Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | CFB | P00751 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984810 | 0.89 | DYRK1A (0.38) | DYRK1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL30855425 | 0.86 | AXL (0.38) | DYRK1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL29196666 | 0.86 | AXL (0.38) | DYRK1AKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL10292445 | 0.81 | PIK3C3 (0.39) | AXLPRKCIBRD4FGFR1FGFR2 | |
| SCHEMBL10326422 | 0.81 | ABL1 (0.37) | ALDH1A1AXLPRKCIBRD4HPGD | |
| SCHEMBL1473221 | 0.81 | BRD4 (0.40) | KMT2AMEN1BRD4CFBCYP2C9 | |
| Hydrochloric Acid SCHEMBL3558795 | 0.79 | BRD4 (0.39) | KMT2AMEN1BRD4CFBCYP2C9 | |
| SCHEMBL3570127 | 0.79 | BRD4 (0.36) | BRD4CFB | |
| SCHEMBL1472560 | 0.79 | BRD4 (0.37) | DYRK1APRKCIBRD4CFB | |
| Hydrochloric Acid SCHEMBL17843977 | 0.77 | BRD4 (0.36) | DYRK1APRKCIBRD4CFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20240208980-A1 | Fostemsavir Intermediates and Process for the Preparation Thereof | NAVINTA, LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2024-03-28 | — | — | US | disclosed |
| WO-2023239729-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-12-14 | — | — | WO | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040023982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1363705-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| US-20030181463-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-09-25 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | DYRK1A 3956/4885KMT2A 941/4885MEN1 4153/4885 |
| US-20240208980-A1 | Fostemsavir Intermediates and Process for the Preparation Thereof | FIP1L1, CYP3A4, FOS | DYRK1A 3911/4885KMT2A 2959/4885MEN1 2662/4885 |
| US-20240101531-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNA1, KCNB1, KCNB2 | DYRK1A 713/4885KMT2A 692/4885MEN1 507/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | DYRK1A 4700/4885KMT2A 1845/4885MEN1 4510/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | DYRK1A 3741/4885KMT2A 1429/4885MEN1 2393/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885KMT2A 1565/4885MEN1 2462/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885KMT2A 1565/4885MEN1 2462/4885 |
| US-20040023982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, EIF2AK2 | DYRK1A 3932/4885KMT2A 997/4885MEN1 3938/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | DYRK1A 4677/4885KMT2A 2481/4885MEN1 4704/4885 |
| US-20030181463-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | DYRK1A 3956/4885KMT2A 941/4885MEN1 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.